Combined low-dose chemotherapy inhibiting angiogenesis and growth of Lewis lung cancinoma xenografts in mice

Journal of Sichuan University (Medical Science)

Volumn 37, Issue 4, 2006, Pages 534-537

  Qiu, Meng ^a   Yi, Cheng ^a   Hou, Mei ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Antiangiogenesis; Chemotherapy; Cyclophosphamide; Low dose; Paclitaxel

Indexed keywords

CD31 ANTIGEN; CYCLOPHOSPHAMIDE; PACLITAXEL; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CONTROLLED STUDY; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LEWIS CARCINOMA; LOW DRUG DOSE; LUNG CANCER; MICROVASCULATURE; MOUSE; NONHUMAN; TUMOR VOLUME; XENOGRAFT;

EID: 33746627255     PISSN: 1672173X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Browder T, Butterfeld CE, Kvaling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res, 2000;60(7): 1878-1886.
2. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest, 2000;105(8):1045-1047.
3. Lennernas B, Alberfesson P, Lennernas H, et al. Chemotherapy and antiangiogenesis: drug-specific, dose-related effects. Acta Oncol, 2003;42(6):294-303.
4. Klement G, Huang P, Mayer B, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res, 2002;8(1):221-232.
5. Lau DH, Xue L, Young LJ, et al. Paclitaxel (Taxol): an inhibitor of angiogenesis in highly vascularized transgenic breast cancer. Cancer Biother Radiopharm, 1999;14(1):31-36.
6. Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res, 2000;6(12): 4874-4884.
7. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med, 1991;324(1):1-8.
8. Lennernas B, Alberfesson P, Lennernas H, et al. Chemotherapy and antiangiogenesis: drug-specific, dose-related effects. Acta Oncol, 2003;42(4):294-303.
9. Trai PA, Willner D, Bianchi AB, et al. Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin. Clin Cancer Res, 1999;5 (11):3632-3638.
10. Bocci G, Francia G, Man S, et al. Thrombospondin I, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA, 2003;100(22): 12917-12922.